Edgewise Therapeutics Reports First Patient Dosing in P-II Study of EDG-7500 to Treat Obstructive Hypertrophic Cardiomyopathy
Shots:
- Edgewise has dosed the first patient in the P-II (CIRRUS-HCM) study of EDG-7500, assessing the safety, PK, and PD in patients (≤30 adults) with obstructive HCM. The patient in Part A of the study will receive EDG-7500 as a single oral dosage, and in Part B, the company expects to administer EDG-7500 as multiple oral doses (=28 days)
- EDG-7500 is an oral, selective cardiac sarcomere modulator that works by reducing early contraction velocity and treating poor cardiac relaxation in HCM and other diastolic dysfunction conditions
- Single dose arm data of EDG-7500's P-II and P-I study is anticipated in Q3'24 and also expects to initiate 28-day study in obstructive and non-obstructive HCM patients in H2'24. To begin the open-label extension trial of EDG-7500 in Q4'24
Ref: Edgewise Therapeutics | Image: Edgewise Therapeutics
Related News:- Edgewise Therapeutics Reports 6-Month Interim (ARCH) Study Results of EDG-5506 for Becker Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
